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Objective: We investigated the efficacy of directly injecting a plasmid with com-
plementary DNA encoding human hepatocyte growth factor into ischemic canine
myocardium to induce angiogenesis.
Methods: Four weeks after ligation of the left anterior descending coronary artery,
125 g of a complementary DNA plasmid encoding the gene for either hepatocyte
growth factor (n  8) or LacZ (transfection control group, n  8) was injected
directly into the myocardium at the border between the normal tissue and the
infarction. Eight other dogs were used as a sham control group. Regional thickening
fraction, which indicated contractile function, and blood flow in the normal (cir-
cumflex branch territory) and ischemic areas were evaluated under dobutamine
administration just before and 4 weeks after transfection. The animals were killed,
and capillary numbers in both areas were assessed. These data in the ischemic area
were evaluated as the percentage of those in the normal.
Results: The number of myocardial capillaries in the ischemic area was successfully
increased to approximately 140% of usual in the hepatocyte growth factor group,
whereas no change was observed in the other groups (P  .0017 by analysis of
variance). Furthermore, regional thickening fraction and blood flow in the ischemic
area, which had deteriorated after coronary ligation, showed significant improve-
ment in the hepatocyte growth factor group relative to the other groups (thickening
fraction P  .0001 by analysis of variance, blood flow P  .0005 by analysis of
variance).
Conclusions: These results support the efficacy of the direct injection of plasmid
complementary DNA encoding human hepatocyte growth factor to induce thera-
peutic angiogenesis in the ischemic myocardium.
Despite major advances in both surgical and catheter revasculariza-tion for ischemic heart disease, some patients cannot benefit fromthese treatments because of diffuse coronary artery lesions, re-peated previous interventions, or low tolerance for surgical stress.In such cases new vasculature that is induced by some agent,therapeutic angiogenesis,1 might supply blood flow to the isch-
emic lesion and thus bring benefits comparable to those seen with either catheter
angioplasty or surgical grafting.
Recent studies have shown that some growth factors have a potent ability to
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induce angiogenesis.2-9 One of the most powerful of these,
vascular endothelial growth factor (VEGF), is reported to
promote angiogenesis in the limbs and heart when admin-
istered as either recombinant protein or complementary
DNA (cDNA) in ischemic animal models.2-7 A clinical trial
with VEGF is underway.10,11
Hepatocyte growth factor (HGF), another potential ther-
apeutic agent, was originally identified and characterized as
a potent mitogen for hepatocytes.12 It has since become
clear that HGF is a mesenchyme-derived pleiotropic factor
that regulates cell growth, cell motility, and the morphogen-
esis of various cell types.13 HGF is also known to stimulate
endothelial cell growth without inducing the replication of
vascular smooth muscle cells; thus HGF has a potent ability
to induce angiogenesis.14-17 Moreover, c-Met, the specific
receptor of HGF, is upwardly regulated in ischemic myo-
cardium.18,19 With this body of evidence as a working basis,
the ability of human recombinant HGF to induce therapeutic
angiogenesis in the rabbit ischemic hind limb was tested and
demonstrated.20 However, the efficacy of HGF to stimulate
angiogenesis in the ischemic heart has not yet been well
examined. In particular, investigations aimed at clinical
applications are lacking.
Virus-mediated gene delivery into organs in vivo has
advantages in terms of efficiency. However, several prob-
lems remain to be resolved before this method can be
applied to the clinical setting, especially with respect to
safety for systemic organs. In contrast, localized transfec-
tion of naked cDNA as a plasmid, without vectors, is
considered to be safer but has a low efficiency of transfec-
tion. In this study we investigated the feasibility of direct
injection of naked cDNA encoding HGF as a therapeutic
angiogenic agent in an ischemic canine heart model.
Material and Methods
Left Coronary Artery Ligation Model
Twenty-four beagles of both sexes weighing 8 to 10 kg were used
in these experiments. All animals received humane care in com-
pliance with the “Principles of Laboratory Animal Care” formu-
lated by the National Society for Medical Research and the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996. After intramuscular sedation with ketamine (10 mg/kg) and
intravenous administration of sodium pentobarbital (10 mg/kg),
the dogs were intubated endotracheally under mechanical ventila-
tion, and anesthesia was maintained with 1% sevoflurane inhala-
tion. Minimal left thoracotomy was performed through the fourth
intercostal space, and a pericardiotomy was made. The left anterior
descending coronary artery was carefully dissected and ligated just
distal of the first diagonal branch. The pericardium and chest were
closed in layers, and the animals were allowed to recover.
Target Region of Gene Transfection
Four weeks after the coronary ligation, thoracotomy through the
left fifth intercostal space was performed on the animals with the
same anesthesia protocol described previously. In all animals
infarcted myocardium caused by previous ligation was visible as a
white scar along the left anterior descending coronary artery. The
ischemic area targeted by gene transfection was established at the
border zone between the normal and the infarcted areas by visual
inspection. To confirm adequacy of the area as potentially isch-
emic, we used epicardial echocardiography and epicardial crystal
pulsed Doppler technique to examined the attenuation of contrac-
tile function with dobutamine administration. In the following
protocols of functional measurement, myocardial ischemia in the
target region was induced by dobutamine administration of 20
g/(min  kg). The normal myocardium control area was chosen
from the circumflex coronary artery territory.
Human Hepatocyte Growth Factor Complementary
DNA Plasmid Preparation and Injection
Human HGF (hHGF) cDNA was inserted into the NotI site of the
pUC-SR expression vector. After assessment of the regional left
ventricular function and blood flow, 0.9 mL of plasmid solution
containing 125 g cDNA was injected directly into the myocar-
dium of the target area at six points with a 1-mL syringe and
27-gauge needle. Sixteen dogs were divided into two groups
according to the type of cDNA injected, hHGF cDNA plasmid
(HGF group, n  8) or LacZ cDNA plasmid (LacZ group, n  8).
Eight other dogs in which the left anterior descending coronary
artery was ligated underwent thoracotomy but were not injected
with cDNA (sham control group, n  8). The injected area was
marked with 5-0 polypropylene epicardial sutures. Four weeks
after the cDNA injection, the animals were anesthetized, and
regional cardiac function and blood flow were evaluated again. At
the end of study period, the dogs were killed with an overdose
intravenous injection of potassium, and the hearts were removed
for further analysis.
Assay of Human Hepatocyte Growth Factor
To perform the enzyme-linked immunosorbent assay (ELISA) of
hHGF in the treated myocardium, 3 dogs from each group were
killed 5 days after the cDNA injection, and their hearts were
excised. The hearts were dissected, and blocks of myocardium
from the treated and control regions were obtained according to the
previous marking suture. The level of hHGF in the myocardium
was estimated with an anti-hHGF monoclonal antibody (Institute
of Immunology, Tokyo, Japan). The antibody that we used in the
ELISA specifically detects hHGF but not endogenous canine HGF.
Assessment of Regional Cardiac Function
Regional myocardial function was evaluated by left ventricular
wall thickening fraction (TF) with the epicardial crystal pulsed
Doppler technique.21 To estimate the left ventricular wall thick-
ness, ultrasonic crystals (WT-20; Crystal Biotech, Hopkinton,
Mass) were implanted into the epicardium both in the territory of
circumflex coronary artery (normal area) and close to the gene
injection site (ischemic area). For pressure measurement and in-
stantaneous pressure (dp/dt) monitoring, an 8F catheter-tip micro-
manometer (Millar Instruments, Inc, Houston, Tex) was intro-
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duced into the left ventricle through its apex. Wall thickness, left
ventricular pressure, and dp/dt data were recorded and analyzed
with computer software (MacLab v3.5/c; AD Instruments Pty Ltd,
Castle Hill, New South Wales, Australia). After stabilization, data
on each parameter were collected at rest and under stress from
administration of dobutamine to cause an ischemic condition.
Dobutamine administration was started at 5 g/(kg  min) and
raised every 10 minutes to a final dose of 20 g/(kg  min). TFs of
left ventricular wall in normal and ischemic regions were calcu-
lated from the collected data as follows:
TF 
end-systolic thickness  end-diastolic thickness
end-diastolic thickness  100%
Myocardial Blood Flow Measurement
After the measurement of cardiac function, colored microspheres
were used to evaluate myocardial blood flow in both the ischemic
and normal regions. About 3 million colored microspheres (Triton
Technology Inc, San Diego, Calif) suspended in 10 mL saline
solution were injected through the left atrial appendage during 20
seconds. Reference blood sampling was started 5 seconds before
the injection of the microsphere solution, and 9 mL blood was
withdrawn at a constant rate of 6 mL/min through a cannula
inserted into the femoral artery. For the assessment 4 weeks after
the cDNA injection, after the functional measurement and blood
draw were completed, the animal was killed and the heart was
excised. The microsphere-determined perfusion flow was mea-
sured by a spectrophotometry method.22 Myocardial samples of
approximately 1 g each were taken from the ischemic, gene-
injected territory and the normal myocardium. The myocardial
samples and reference blood samples were digested overnight in
10 mL of 10-mol/L potassium hydroxide. The microspheres were
extracted with dimethylformaldehyde, and the optical density
(OD) of the dye was analyzed with a spectrophotometer (UV-
160A; Shimadzu Inc, Tokyo, Japan). From the OD measured, the
myocardial blood flow was calculated according to the following
equation:
Blood flow in tissue sample 
withdrawal rate
tissue sample weight 
OD of tissue sample
OD of reference blood sample
where blood flow is in milliliters per minute per gram, withdrawal
rate is in milliliters per minute, and weight is in grams.
In Vitro Histologic Assessment
The excised hearts from all the animals were cut, and tissue
specimens were obtained as transverse sections from the ischemic,
cDNA-injected area and the normal area. Both myocardial samples
were embedded in compound (Tissue-Tek; Sakura Finetechnical
Co, Ltd, Tokyo, Japan) and frozen in liquid nitrogen. Frozen 5-m
thick sections were cut transversely from each specimen with a
cryostat. To count the capillaries in the myocardium, epithelial
cells were detected by staining the frozen sections immunohisto-
logically with an antibody to von Willebrand factor with the Dako
Enhanced Polymer One-step Staining kit (DAKO Japan Co Ltd,
Kyoto, Japan). The peroxidase was visualized by incubation with
DAB, followed by incubation with a DAB-enhancing solution
(DAKO). Ten different fields at 200 magnification were ran-
domly selected, and the number of capillaries in each field was
counted. The average density of capillaries in the DNA-injected
area was expressed as the percentage of the average capillary
density in the normal area.
Safety Issues
To assess the adverse effects of this protocol, the electrocardio-
gram was monitored to detect arrhythmia during the entire exper-
imental protocol, and the leukocyte count and serum hHGF levels
were measured in 3 dogs from each group 1, 3, 5, 7, and 14 days
after cDNA injection. The serum HGF level was assessed with the
ELISA system described previously.
Statistical Analysis
All values are expressed as mean  SD. A 1-way analysis of
variance, followed by the Bonferroni test, was used to compare the
means of the three groups.
Results
Overexpression of Human Hepatocyte Growth Factor
in the Myocardium after Plasmid Injection
To ensure that our method resulted in sufficient production
of HGF, the hHGF content in the myocardium samples
obtained from the cDNA-injected area was determined with
an ELISA assay. The result was 4.7  1.7 ng/g tissue in the
HGF group, whereas hHGF was undetectable in the LacZ
and sham control groups (Figure 1). Samples obtained from
the normal areas in all groups contained no hHGF protein.
Immunohistochemical Staining and Capillary Density
Four weeks after the HGF transfection, the capillary density
in the ischemic region was the same as in the nonischemic
region in the LacZ and sham control groups, whereas a
significant increase to approximately 140% of the value in
the normal area was shown in the HGF group (capillary
Figure 1. Comparison of hHGF protein contents in myocardium of
cDNA-injected ischemic region measured 5 days after gene de-
livery in HGF (Group H), LacZ (Group L), and sham control (Group
S) groups. Bar heights represent mean; error bars represent SD.
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density 137.0%  22.5% in HGF group vs 97.6%  12.2%
in LacZ group vs 95.0% 9.1% in sham control group, P
.0017; Figures 2 and 3).
Recovery of Regional Contraction and Perfusion
In light of these results, we analyzed the efficacy of hHGF
plasmid injection with respect to the regional contractile
function and blood supply. TF, as an indicator of contrac-
tion, and blood flow were measured under dobutamine
administration stress to induce ischemia. Both parameters in
the ischemic region were evaluated as the percentage of the
same measurement in the normal area of the same heart. TF
in the ischemic area, which had deteriorated as a result of
the coronary ligation (33.5%  13.7% in HGF group vs
31.7%  7.7% in LacZ group vs 27.1%  10.1% in sham
control group), showed significant improvement 4 weeks after
injection only in the HGF group (78.1%  11.2% in HGF
group vs 26.9% 14.5% in LacZ group vs 22.7% 12.6% in
sham control group, P .0001, Figure 4). Regional blood flow
in the ischemic area was also restricted in all groups (67.3%
9.8% in HGF group vs 54.4%  16.5% in LacZ group vs
62.4% 13.0% in sham control group), and recovered signif-
icantly only in the HGF group (104.6% 9.3% in HGF group
vs 58.0% 20.2% in LacZ group vs 61.0% 13.6% in sham
control group, P  .0005; Figure 5).
Safety of Direct Injection of Hepatocyte Growth
Factor Complementary DNA Plasmid
No animals died unexpectedly during the study period.
The effect of overexpressed HGF on the living body was
Figure 2. Representative immunohistologic staining by von Willebrand antibody of ischemic myocardium taken
from cDNA-treated area 4 weeks after gene transfection (original magnification 200). A, Treated with cDNA
encoding HGF; B, treated with cDNA encoding LacZ.
Figure 3. Comparison of capillary densities in cDNA-treated isch-
emic myocardium 4 weeks after gene delivery in HGF (Group H),
LacZ (Group L), and sham control (Group S) groups. Bar heights
represent mean; error bars represent SD. Asterisk indicates P 
.0018 versus LacZ group; dagger indicates P  .0011 versus sham
control group.
Figure 4. Comparison of wall contractile function evaluated by TF
in cDNA-treated ischemic region with administration of dobut-
amine (20 g/[kg  min]) in HGF (squares), LacZ (circles), and
sham control (triangles) groups. Results are expressed as per-
centage of value in normal area. Data points represent mean;
error bars represent SD. Asterisk indicates P < .0001 versus LacZ
group; dagger indicates P < .0001 versus sham control group.
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evaluated with a serial leukocyte count, assessment of the
serum hHGF level, and an electrocardiogram. The leu-
kocyte count, which had risen immediately after the
cDNA injection, was reduced promptly to the normal
range within a week, and the changes in the leukocyte
count in time were similar in the three groups (data not
shown). No hHGF was detected in the serum in any group
during the study period. Furthermore, no critical arrhyth-
mias were observed during postoperative electrocardio-
gram monitoring, although some paroxysmal ventricular
beats were observed during the direct injection of the
cDNA plasmid into the myocardium.
Discussion
The potent capability of humoral growth factors, repre-
sented by VEGF and fibroblast growth factor, to induce new
vessel formation has been shown in many animal models of
ischemic limb and heart.2-9 Recently, in addition to these
factors, HGF was also shown to have an angiogenic effect
by stimulating epithelial cell growth without causing
smooth muscle cell replication.14-17
In this study we successfully demonstrated that transfer
of the cDNA encoding hHGF by direct injection of a plas-
mid resulted in increases in regional capillary density and
regional blood supply in the ischemic canine heart. Further-
more, this angiogenic effect was associated with improve-
ment in the regional contractile function during stress-in-
duced ischemia. This is the first report to our knowledge to
attest to the efficacy of the direct injection of the gene for
hHGF by plasmid for the potential clinical application of
angiogenesis therapy in the ischemic heart.
In our study the number of capillaries had increased 4
weeks after treatment, although the increase in large-caliber
vessels was limited. The improvement of regional blood
flow in the treated myocardium seemed to be more than
expected from the increase of capillary density. We specu-
late that some endogenous factors, such as nitric oxide
derived from the endothelium of newly formed capillaries,
may play a role in the recovery of blood perfusion.
Several methods for gene delivery have been established,
and some of them are already being applied in clinical
investigations, including transcoronary or myocardial injec-
tion and transfection with a viral vector11 or a naked plas-
mid.10 Rosengart and colleagues11 showed successful clin-
ical improvement in ischemic heart disease with direct
myocardial injection of adenoviral-mediated cDNA encod-
ing VEGF. On the other hand, Losordo and colleagues10
reported comparable results by direct myocardial injection
of a cDNA plasmid encoding human VEGF. In our study we
used direct injection of the cDNA plasmid as the gene
delivery system, in the same manner as Losordo and col-
leagues.10 Obviously the efficiency of transfection and the
subsequent protein expression resulting from direct injec-
tion of plasmid cDNA could be lower than that obtained
with virus-mediated transfection. However, cDNA plasmid
injection has been shown previously to yield expression of
a reporter gene for longer than a month.23 Furthermore, we
confirmed the expression of the cDNA that we transfected
into the myocardium by plasmid injection, indicating the
feasibility of this method for gene transfer.
Indeed, the concentrations of HGF protein that we de-
tected in our myocardial samples were somewhat low com-
pared with those obtained with the hemagglutinating virus
of Japan–mediated intracoronary infusion that we reported
previously.18 However, HGF, a secreted protein, can act in
an autocrine-paracrine manner,14,24 and thus a lower quan-
tity of continuously expressed protein could be sufficient to
induce angiogenesis and support the subsequent recovery of
regional cardiac function in vivo, as Losordo and col-
leagues10 have shown.
Some adverse effects from these angiogenic growth fac-
tors have been seen; the formation of tumor vessels, such as
hemangiomas, may be one of the most serious problems. In
a previous study, the unregulated expression of VEGF in the
heart led to the formation of hemangiomalike vessels.6, 25 In
this study no tumorlike vessels were seen in the heart 4
weeks after HGF transfection. Indeed, it is to be expected
that the expression of excessively high levels of HGF would
result in the abnormal growth of new vessels. However, the
direct injection of the cDNA plasmid, which induces the
expression of relatively small amounts of protein, might not
cause such adverse phenomena.
Overexpression of HGF has been shown to induce an-
giogenesis directly and indirectly through the activation of
VEGF gene transcription.26 In its signaling pathway, HGF is
upstream of VEGF; thus gene therapy with HGF is expected to
Figure 5. Comparison of blood perfusion in cDNA-treated isch-
emic region with administration of dobutamine (20 g/[kg  min])
in HGF (squares), LacZ (circles), and sham control (triangles)
groups. Results are expressed as percentage of value in normal
area. Data points represent mean; error bars represent SD. As-
terisk indicates P  .0004 versus LacZ group; dagger indicates
P  .0006 versus sham control group.
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have an angiogenic effect comparable or superior to that of
VEGF, although no confirmation has yet been obtained. Sev-
eral clinical trials aimed at therapeutic angiogenesis with
VEGF gene transfection with adenoviral vectors11 as well as
plasmids10 have been initiated, and the short-term results have
been reported to be satisfactory. These successes have encour-
aged us to plan direct injection of a plasmid containing cDNA
encoding hHGF in cases of otherwise untreatable ischemic
heart disease in the near future.
There may be other advantages to using HGF in prefer-
ence to other growth factors to treat the ischemic heart. For
example, in addition to its angiogenic effects, HGF has
other physiologic activities, such as antiapoptosis and
antifibrosis. We have previously demonstrated the ame-
lioration of ischemia-reperfusion injury and infarcted
area by HGF through its antiapoptotic effect.18,27 These
effects may contribute to the functional recovery of the
ischemic heart. In contrast, VEGF is known to have
adverse effects, such as increasing the membrane perme-
ability,28 which may lead to myocardial edema. Further
investigation is required to ascertain the therapeutic su-
periority of HGF or VEGF.
Although the overall clinical results from coronary
artery bypass grafting and percutaneous transluminal cor-
onary angioplasty are improving, some patients with
ischemic heart disease have untreatable coronary lesions.
Most of these patients have critical symptoms caused by
the ischemic myocardium that may progress to ischemic
cardiomyopathy. In this study we showed the efficacy of
hHGF plasmid treatment, which induced neoangiogen-
esis in the ischemic myocardium, improving regional
myocardial perfusion and contractile function. We be-
lieve that this treatment would be an invaluable option
for such a patient, either combined with coronary artery
bypass grafting or as a sole therapy.
There are several limitations to our study. First, dogs are
known to have native collateral vessels in heart. Therefore
it is possible that such native collateral formation affected
the functional recovery. Second, our definition of the isch-
emic region was imprecise to some extent, because we
performed acute coronary ligation. Indeed, the determina-
tion of ischemic myocardium induced by dobutamine ad-
ministration was difficult and relatively subjective, whereas
we could check the infarcted myocardium visually. Third,
we did not assess the size of infarction. The effect of HGF
treatment for infarcted myocardium was not assessed in this
study, and further investigation is required.
In conclusion, we confirmed the efficacy of injection into
the ischemic myocardium of a plasmid encoding hHGF as
an angiogenic therapy. These results support the application
of hHGF plasmid gene therapy to the clinical setting. The
simplicity of this procedure is especially attractive for high-
risk patients, either as a sole therapy or combined with
conventional coronary artery bypass grafting.
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